Bloomberg Tobacco Grants Face Scrutiny as New GSTHR Report Highlights Global Shift to Safer Nicotine

A new round of Bloomberg-funded tobacco-control grants has reignited debate over how international donors influence nicotine policy in lower- and middle-income countries, just as new evidence suggests millions of consumers are moving away from combustible cigarettes towards smoke-free alternatives.

The Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA) has recently questioned whether the Bloomberg Initiative to Reduce Tobacco Use (which we already know does not have the best reputation), administered through Vital Strategies, gives sufficient space to tobacco harm reduction when supporting national policy development.

Its criticism coincides with the publication of The Global State of Tobacco Harm Reduction 2026: A Situation Report, which argues that substitution towards vapes, nicotine pouches, snus and heated tobacco products is becoming an increasingly important feature of the global nicotine market. GSTHR estimates that more than 200 million adults worldwide now use these products, while their growing use has coincided with declining smoking prevalence in 28 countries. Coincidence does not establish that alternative nicotine products caused those declines, but the trends have strengthened calls for policymakers to examine substitution more closely.

The Bloomberg grants are available to government bodies, universities, NGOs, and policy institutes, with strategic funding targeting nine countries, including India, Indonesia, Bangladesh, Pakistan, Vietnam, and the Philippines.

Projects allegedly aim to strengthen tobacco control policies and the WHO’s MPOWER framework. Separate Bloomberg-supported cessation grants can provide up to $400,000 over 24 months, focusing particularly on brief cessation advice, national quitlines, and mobile cessation services.

Such investment can provide obvious benefits where cessation services, surveillance and healthcare resources remain underfunded. CAPHRA’s objection is therefore not to smoking cessation itself. Rather, it rightly highlights that foreign-funded programmes can influence which policy options receive institutional support while tobacco harm reduction remains outside the preferred framework.

The coalition uses the provocative term “philanthropic colonialism” to describe what it considers disproportionate influence by wealthy international organisations over health priorities in developing countries. It wants governments to disclose funding agreements and technical-assistance arrangements and ensure locally accountable debate before adopting nicotine policies.

WHO’s clinical cessation guideline recommends behavioural interventions alongside established pharmacotherapies including varenicline, nicotine replacement therapy, bupropion and cytisine. Expanding access to these treatments remains an important opportunity to reduce smoking.

But the evidence base now extends beyond conventional cessation medicines. The August 2026 update of Cochrane’s living systematic review examined 90 completed studies involving more than 29,000 participants. It found high-certainty evidence that nicotine e-cigarettes increase smoking quit rates compared with NRT, with approximately four additional people quitting per 100 treated.

Cochrane stresses that the evidence of course relates to regulated nicotine e-cigarettes rather than illicit products containing other active substances. For harm reduction advocates, however, the findings raise an important question: should internationally funded cessation strategies disregard a consumer product for which smoking-cessation evidence is now rated high certainty?

The new GSTHR report broadens that question beyond vaping. Knowledge•Action•Change (K•A•C), which produces GSTHR, examines changes between January 2025 and early 2026 involving smoking prevalence, safer nicotine uptake, regulation, pricing and cessation research.

Its central argument is that consumer behaviour is increasingly moving towards non-combustible nicotine even while many governments move towards tighter restrictions or outright bans. GSTHR also highlights comparative pricing as important: when lower-risk alternatives are significantly more expensive or difficult to obtain than cigarettes, switching may become less realistic, particularly for lower-income smokers.

Nicotine pouches, heated tobacco, snus and vaping have different evidence bases and should not be treated as interchangeable. The broader harm reduction principle is that avoiding combustion can substantially change toxicant exposure, while individual products still require appropriate assessment, standards and youth protections.

CAPHRA and GSTHR also raise concerns that bans can create opportunities for illicit markets. India, for example, prohibited e-cigarettes in 2019, yet illegal products continue to be seized. Their continued presence does not prove prohibition inevitably increases illicit consumption, nor does it establish how large the market is. It does demonstrate that legislation alone does not necessarily eliminate demand.

A regulated market can offer governments tools unavailable in illegal supply chains: licensing, ingredient standards, age verification, taxation, and penalties for non-compliance. This is particularly relevant when policies are designed to protect young people. Illicit sellers have little incentive to observe age restrictions or manufacturing requirements.

Tobacco companies have a well-documented history of interfering with public-health policy, making safeguards against commercial influence essential. CAPHRA argues that transparency should nevertheless extend to other organisations seeking to shape regulation.

That could include publishing donor agreements, disclosing externally funded technical assistance, and giving independent researchers, clinicians, and consumer organisations opportunities to participate in consultations under transparent conflict-of-interest rules.

Traditional tobacco control and harm reduction need not compete. Taxes, smoke-free laws, advertising restrictions, cessation medicines and health warnings can operate alongside regulated lower-risk alternatives for adults who smoke.

The dispute surrounding Bloomberg’s grants therefore raises a broader question than who finances tobacco-control programmes. With Cochrane finding high-certainty evidence for vaping as a cessation intervention and GSTHR documenting rapidly expanding use of smoke-free nicotine products, governments increasingly face a choice over whether tobacco policy will respond to changing consumer behaviour—or attempt to restrict it. For tobacco harm reduction experts, international assistance is most valuable when it expands countries’ ability to evaluate the full evidence base rather than predetermining which approaches they may consider.

https://www.vapingpost.com/2023/02/06/bloomberg-invests-420-million-in-more-ineffective-tobacco-control-strategies/